Premium
Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump
Author(s) -
Atiq Omar T.,
Kemeny Nancy,
Niedzwiecki Donna,
Botet Jose
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920215)69:4<920::aid-cncr2820690414>3.0.co;2-y
Subject(s) - medicine , mitomycin c , intrahepatic cholangiocarcinoma , cancer , primary cancer , surgery , oncology , gastroenterology
Abstract Ten patients with unresectable primary liver cancer, eight of whom had elevated serum alpha‐fetoprotein levels, were treated with intrahepatic fluorodeoxyuridine (FUDR) and mitomycin C administered through an implantable pump. Four patients had a partial response, and two had a minor response. The median survival from initiation of treatment was 14.5 months (range, 2 to 32 months), with patients receiving therapy for a median of 11.2 months. In general, the therapy was well tolerated; only one patient had treatment‐related biliary sclerosis. In conclusion, the combination of intrahepatic FUDR and mitomycin C was an effective palliative regimen for unresectable primary liver cancer, even in the presence of elevated serum alpha‐fetoprotein levels. Further studies are needed to confirm these findings and compare this regimen with other methods of treatment for hepatocellular carcinoma. Cancer 1992; 69:920–924.